Delving into the Latest Updates on Inclisiran sodium with Synapse

Overview

Basic Info

Drug Type

siRNA

Synonyms

ALN-PCSsc, Inclisiran, 因利司然

+ [10]

Target

PCSK9

Action

inhibitors

Mechanism

PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors), RNA interference

Therapeutic Areas

Cardiovascular DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication

Homozygous familial hypercholesterolemiaHypercholesterolemiaPrimary Hyperlipidemia+ [15]

Inactive Indication-

Originator Organization

Alnylam Pharmaceuticals, Inc.

Active Organization

Novartis Pharma AGNovartis Pharmaceuticals Australia Pty Ltd.

Novartis Pharmaceuticals Canada, Inc.

+ [8]

Inactive Organization

Alnylam Pharmaceuticals, Inc.

Alcami Corp.

License Organization

National Health Service

The Medicines Co.

Alnylam Pharmaceuticals, Inc.

+ [5]

Drug Highest PhaseApproved

First Approval Date

European Union (09 Dec 2020),

Complex dyslipidemiaPrimary hypercholesterolemia

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

Sequence Code 31593325

Source: *****

Sequence Code 31594604

Source: *****

The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission. To do this, researchers will test the effects of inclisiran compared to placebo, when given with standard treatment.

Start Date03 Oct 2025

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

100 Clinical Results associated with Inclisiran sodium

Login to view more data

100 Translational Medicine associated with Inclisiran sodium

Login to view more data

100 Patents (Medical) associated with Inclisiran sodium

Login to view more data

201

Literatures (Medical) associated with Inclisiran sodium

01 Mar 2026·Molecular Therapy-Nucleic Acids

Ribofuranose-based GalNAc-conjugated siRNA enhances the liver-targeted delivery and elicits robust RNAi-mediated gene silencing

Article

Author: Song, Geng-Shen ; Yu, Fei ; Wang, Jie ; Li, Zhen-Min ; Gao, Zhong-Cai ; Ji, Guang-Shen ; Tian, Zhi-Kang ; Huang, Ze-Ao ; Chen, Ai-Fu

The N-acetylgalactosamine (GalNAc)-conjugate delivery platform has emerged as a pivotal enabling technology for the clinical translation of oligonucleotide therapeutics. The development of GalNAc-conjugated small interfering RNA (siRNA) therapeutics has been significantly advanced through structural optimization of the delivery platform. Here, we report that a series of ribofuranose- and deoxyribofuranose-incorporated GalNAc-siRNA conjugates targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA were synthesized and evaluated for their bioactivities and tissue distribution in vivo. When compared in detail with inclisiran, an approved siRNA drug that incorporates a triantennary GalNAc construct (designated L96) for targeted liver delivery, inc-G5, which contains ribofuranose ring within its GalNAc cluster, exhibits superior efficacy. Additionally, pharmacokinetic (PK) analysis in rats revealed that G5-conjugated siRNAs preferentially accumulate in the liver, have an extended elimination half-life, and exhibit the highest liver-to-kidney ratio, which indicated excellent liver delivery specificity. Moreover, the synthesis of G5 can be readily scaled up to the kilogram level, thereby providing robust support for the production of oligonucleotide drugs. These results underscore the critical application of ribofuranose integration in GalNAc-siRNA drugs, establishing G5 as a promising liver-targeted delivery moiety for siRNAs to achieve sustained gene silencing with improved hepatic specificity and therapeutic durability.

01 Mar 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

A universal LC-HRMS workflow integrating targeted and untargeted strategies for rapid and comprehensive metabolite profiling of oligonucleotide-based therapeutics

Article

Author: Yang, Yue ; Tang, Chongzhuang ; Zhao, Yuqing ; Zhu, Mingshe

Metabolite profiling and identification of oligonucleotide-based therapeutics (OBTs) is important in drug discovery and development. Conventional liquid chromatography-high resolution mass spectrometry (LC-HRMS) methods (using ProMass, BioPharma Finder) are effective for targeted analysis of predictable nuclease-derived metabolites but often miss unexpected non-nuclease-mediated ones. This study aimed to develop a universal analytical workflow for comprehensive metabolite profiling of multiple classes OBTs by integrating BioPharma Finder for targeted identification with a Background Subtraction Filter (BSF) for untargeted detection of unexpected biotransformation products. Inclisiran, a GalNAc-conjugated siRNA, was used as a model compound. Samples incubated with rat, monkey, and human liver S9 fractions were analyzed by the LC-HRMS workflow. As a result, a total of 25 (22 predicted +3 unpredicted) inclisiran metabolites were identified across the three species. BioPharma Finder enabled rapid and sensitive identification of 22 predicted metabolites, supported by automated fragment ion assignment. The BSF data processing revealed 22 metabolites not present in control samples, including SS-1GalNAc, SS-2GalNAc, and SS-3GalNAc, which were missed by BioPharma Finder and likely formed via β-N-acetylglucosaminidase-mediated biotransformation. The structures of BSF-detected metabolites were confirmed by comparison with BioPharma Finder-identified metabolites or characterized through manual MS/MS interpretation. Product ion spectra of these metabolites showed weak or absent diagnostic ion (m/z 94.936), a characteristic fragment of phosphorothioate-containing oligonucleotides, suggesting that the product ion filtering of this ion exhibits limited utility in discovering inclisiran metabolites. Overall, the integrated LC-HRMS workflow shows strong potential as a universal platform for biotransformation studies of OBTs.

01 Feb 2026·DRUGS

Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials

Review

Author: Qiao, Wenmei ; Dou, Lei ; Li, Yongze ; Feng, Yunfei ; Wen, Zhifeng

BACKGROUND:

Elevated lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease, but effective therapies remain limited. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are primarily used to lower low-density lipoprotein cholesterol (LDL-C), yet their effects on Lp(a) have been inconsistently reported. This umbrella review synthesizes meta-analytic evidence on PCSK9 inhibitors and Lp(a).

METHODS:

We systematically searched PubMed, Embase, Web of Science, and Cochrane Library through April 2025 for meta-analyses of randomized controlled trials (RCTs) comparing PCSK9 inhibitors (alirocumab, evolocumab, inclisiran) with placebo or standard therapy. The primary outcome was mean percentage change in Lp(a). Methodological quality was assessed using the Assessment of Multiple Systematic Reviews 2 (AMSTAR-2), and evidence certainty was graded with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Overlap of primary trials was quantified using the Corrected Covered Area (CCA), and sensitivity analyses were performed to account for overlapping evidence.

RESULTS:

Twenty-one meta-analyses (116 RCTs; 231,796 participants) were included. The PCSK9 inhibitors consistently reduced Lp(a): evolocumab (29.68-46.68%; high certainty), alirocumab (18.55-26.46%; high certainty), and inclisiran (18.00%; high certainty). Higher biweekly doses yielded larger decreases (e.g., alirocumab 150 mg: 24.6%; evolocumab 140 mg: 26.8%, high certainty). Reductions were dose-dependent and broadly consistent across populations, comparators, follow-up durations, and baseline Lp(a). The Lp(a) reductions correlated modestly with LDL-C (β = 0.28; 95% CI 0.07-0.49) and apolipoprotein B (apoB) (β = 0.33; 95% CI 0.03-0.63). Concomitant reductions in LDL-C, apoB, and major adverse cardiovascular events were supported by high and moderate certainty evidence. Safety was favorable, with injection-site reactions being the most common adverse event. Sensitivity analyses confirmed robustness of findings after accounting for overlapping trials.

CONCLUSIONS:

The PCSK9 inhibitors, particularly evolocumab 140 mg every 2 weeks, significantly lower Lp(a) alongside LDL-C and apoB. These findings highlight the consistent Lp(a)-lowering effect of PCSK9 inhibitors. However, the observed cardiovascular benefits are largely attributable to concomitant LDL-C reduction, and the incremental contribution of Lp(a) lowering remains uncertain. Confirmation from outcome trials specifically designed to target Lp(a) is required.

REGISTRATION:

PROSPERO CRD420251048597.

310

News (Medical) associated with Inclisiran sodium

06 Mar 2026

·www.pharmaceutical-technology.com

Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal

Alnylam will hand over $10m upfront to secure access to 15 novel genetic targets identified by Tenaya for heart disease. Credit: surprisestock / Shutterstock.com. Alnylam Pharmaceuticals has forged a discovery collaboration worth up to $1.23bn with cardiovascular disease specialist, Tenaya Therapeutics. Through this partnership, Alnylam will harness Tenaya’s capabilities to identify up to 15 novel genetic targets involved in heart disease. In return, Alnylam will hand over up to $10m upfront, while pledging to pay out up to $1.13bn in development and commercial milestone payments linked to any drugs created through the partnership. However, Tenaya bears responsibility to yield targets up to Alnylam’s standards, as the $10m upfront fee could be subject to a $500k reduction per candidate for up to eight nominated targets that don’t meet the latter company’s criteria. Once these targets have been identified, Alnylam and Tenaya will collaborate for around two years to mutually validate them through both in vitro and in vivo methods. Under the terms of this deal, Alnylam will reimburse Tenaya for “full-time employees and out-of-pocket costs and expenses”, as per a filing with the US Securities and Exchange Commission (SEC). After Tenaya has fulfilled its end of the deal, Alnylam is hoping to harness these targets to create disease-modifying therapies (DMTs) for heart disease, though no fine details on specific indications were shared. Alnylam will assume responsibility for the subsequent development and commercialisation of any drugs created from the targets identified through this partnership. Alnylam sets heart on cardiovascular market This deal could see Alnylam further its presence in the cardiovascular market, as the company recently secured US and EU approval for its silent interfering RNA (siRNA) therapy, Amvuttra (vutrisiran), in ATTR amyloidosis with cardiomyopathy (ATTR-CM). Analysts at GlobalData, parent company of Pharmaceutical Technology , forecast that Amvuttra will bring in $7.8bn for the company in 2031, meaning the drug will likely continue to be Alnylam’s most lucrative asset. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Alnylam was also responsible for the co-development of Novartis’ blockbuster cholesterol-lowering therapy, Leqvio (inclisiran), which GlobalData forecasts will make $3.9bn in 2031. Novartis previously absorbed the commercialisation rights to the drug through its $9.7bn acquisition of Alnylam’s Leqvio development partner, The Medicines Company, in 2019. To expand its reach in this market, Alnylam is also running late-stage clinical trials on its investigational assets. This includes the Phase III HELIOS-B study (NCT04153149) evaluating vutrisiran in ATTR-CM, as well as the Phase III ZENITH (NCT07181109) trial assessing zilebesiran for the treatment of hypertension alongside collaborator, Roche. Cardiovascular deals garner interest In recent times, there has been a notable uptick in pharma deals within the cardiovascular disease space. In February 2026, GSK acquired Canadian biotech 35Pharma for $950m , thus absorbing its range of investigational new drug (IND)-stage candidates for both cardiopulmonary diseases and heart failure. Meanwhile, Novartis inked a research partnership with Unnatural Products (UNP) worth up to $1.7bn in the same month, which will see the pair join forces to develop macrocyclic peptide-based therapies for cardiovascular disease. According to GlobalData’s Pharmaceutical Intelligence Center, M&As were the most common form of cardiovascular-centric deal in 2025, forming 44% of the agreements during the year.

AcquisitionPhase 3

05 Mar 2026

·allsci.com

Alnylam looks to Tenaya for new RNAi cardiovascular target candidates in USD 1.2b deal

US-based biotechs Tenaya Therapeutics, Inc. (Nasdaq: TNYA) and Alnylam Pharmaceuticals (Nasdaq: ALNY) entered into a research collaboration agreement to discover and validate novel genetic targets for the development of RNA interference cardiovascular disease therapeutics. Under the deal, Tenaya will apply its proprietary target identification and validation platform to validate up to 15 gene targets over a two-year term, after which Alnylam will hold responsibility for all development and commercialization of RNAi-based therapeutics against validated targets. No drug candidates or specific molecular targets were disclosed within the announcement. Tenaya will receive up to USD 10 million in upfront payments along with reimbursement for research costs incurred during the two-year validation period. Alnylam will be responsible for funding all downstream development and commercialization. Tenaya is eligible for up to USD 1.13 billion in development and commercial milestone payments contingent on all 15 validated genetic targets heart disease programs reaching approval. The collaboration leverages complementary capabilities from each company. Tenaya contributes a suite of integrated tools for modality-agnostic target identification and validation, including human induced pluripotent stem cell-derived cardiomyocytes, high-throughput in vitro screening, imaging analysis, machine learning algorithms, and engineered heart tissue models. The company states these capabilities have generated more than 150 genetic targets to date and contributed to its clinical-stage pipeline, which includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy; TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy; and TN-301, a small molecule HDAC6 inhibitor for heart failure. Alnylam brings its established RNAi therapeutics platform, which uses small interfering RNAs conjugated to GalNAc delivery systems to silence disease-driving genes at the mRNA level in hepatocytes. The collaboration expands the firm’s cardiovascular disease pipeline by sourcing novel genetic targets, and follows Alynlam’s August 2025 collaboration with Scenic Biotech for novel drug discovery, and a 2021 deal with PeptiDream for the discovery and development of peptide-siRNA conjugates. Alnylam has previously applied its RNAi platform to cardiovascular targets including PCSK9, leading to the discovery of inclisiran, licensed to The Medicines Company and subsequently acquired by Novartis in January 2020 as part of a USD 9.7 billion acquisition. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

AcquisitionGene TherapyLicense out/in

03 Mar 2026

·www.biospace.com

Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors

Dr. Maraganore brings more than three decades of experience leading discovery, development and commercialization of groundbreaking medicines Founding CEO of Alnylam Pharmaceuticals led company through global approval and commercialization of its first five RNAi medicines SAN DIEGO , March 3, 2026 /PRNewswire/ -- Protego Biopharma, Inc., a clinical-stage biotechnology company dedicated to pioneering first-in-class small molecule therapeutics that reprogram protein folding to address systemic amyloid diseases and other protein misfolding disorders, today announced the appointment of John M. Maraganore, Ph.D., to its Board of Directors. Dr. Maraganore is a highly accomplished life sciences industry leader widely recognized for his contributions to the discovery, development, and commercialization of groundbreaking medicines. "It's an honor to have a luminary like Dr. Maraganore join Protego's Board of Directors," said Brent Warner, Protego's CEO. "His reputation in the biotech industry precedes him, as he is widely respected for successfully tackling some of the most complex scientific and commercial challenges. His insight and expertise will be invaluable as we move our programs forward." For more than three decades, Dr. Maraganore has held leadership roles at a range of biotechnology and pharmaceutical organizations and has served as a board member and advisor for numerous public and private biotech companies and industry organizations. "Targeting protein misfolding pathways is an exciting frontier in biomedical science and holds the promise of new treatments for monogenic protein misfolding diseases that cause a range of illnesses," Dr. Maraganore said. "I'm eager to play a role, especially as Protego advances its lead drug candidate into a pivotal clinical trial for AL amyloidosis, a rare and often fatal condition caused by protein misfolding." Dr. Maraganore was the founding CEO and a Director of Alnylam Pharmaceuticals from 2002 to 2021, leading the company from early RNA interference (RNAi) research to the global approval and commercialization of its first five RNAi medicines: ONPATTRO®, GIVLAARI®, OXLUMO®, Leqvio®, and AMVUTTRA®. During his time with the company, he built Alnylam into an industry leader with more than $25 billion in market capitalization and more than 20 pharmaceutical partnerships. He continues to serve on the company's Scientific Advisory Board. He served in a senior leadership role at Millennium Pharmaceuticals, overseeing oncology, cardiovascular, inflammatory, and metabolic franchises, as well as M&A and strategy. Earlier in his career at Biogen, he invented and led the development of ANGIOMAX® (bivalirudin). He also held scientific roles at ZymoGenetics and The Upjohn Company. He currently serves as Co-CEO of cardiovascular medicine company, Corsera Health, Venture Partner at ARCH Venture Partners, Venture Advisor at Atlas Ventures, Executive Partner at RTW Investments, and Senior Advisor at Blackstone. He is a director of several public companies, including Beam Therapeutics, Kymera Therapeutics, and Takeda Pharmaceuticals, and chairs or serves on the boards of multiple private biotechnology companies. Dr. Maraganore serves on the Board of BIO (Chair, 2017–2019; Chair Emeritus), the Termeer Foundation, and several advisory boards supporting innovation in life sciences. He earned his B.A., M.S., and Ph.D. in biochemistry and molecular biology from the University of Chicago. About Protego Biopharma Protego Biopharma is a San Diego-based biotech company focused on developing small-molecule drugs that target protein misfolding pathways. By reprogramming cellular processes to restore proper protein function, Protego aims to treat rare and systemic diseases with precision and improved patient outcomes. For more information, visit . View original content to download multimedia: SOURCE Protego Biopharma

Executive Change

100 Deals associated with Inclisiran sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Inclisiran sodium	C10AX	DB14901

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Homozygous familial hypercholesterolemia	United States	Novartis Pharmaceuticals Corp.	12 Feb 2026
Hypercholesterolemia	Japan	Novartis Pharma KK	25 Sep 2023
Primary Hyperlipidemia	United States	Novartis Pharmaceuticals Corp.	07 Jul 2023
Atherosclerosis	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	14 Sep 2021
Heterozygous familial hypercholesterolemia	Canada	Novartis Pharmaceuticals Canada, Inc.	26 Jul 2021
Hypercholesterolemia, Familial	Canada	Novartis Pharmaceuticals Canada, Inc.	26 Jul 2021
Complex dyslipidemia	European Union	Novartis Europharm Ltd.	09 Dec 2020
Complex dyslipidemia	Iceland	Novartis Europharm Ltd.	09 Dec 2020
Complex dyslipidemia	Liechtenstein	Novartis Europharm Ltd.	09 Dec 2020
Complex dyslipidemia	Norway	Novartis Europharm Ltd.	09 Dec 2020
Primary hypercholesterolemia	European Union	Novartis Europharm Ltd.	09 Dec 2020
Primary hypercholesterolemia	Iceland	Novartis Europharm Ltd.	09 Dec 2020
Primary hypercholesterolemia	Liechtenstein	Novartis Europharm Ltd.	09 Dec 2020
Primary hypercholesterolemia	Norway	Novartis Europharm Ltd.	09 Dec 2020

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Coronary Syndrome	Phase 3	China	Novartis Pharmaceuticals Canada, Inc.	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Japan	Novartis Pharmaceutical Manufacturing GmbH	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Japan	Novartis Pharma AG	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Japan	Novartis Pharmaceuticals Canada, Inc.	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Japan	Corden Pharma SpA	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Argentina	Novartis Pharma AG	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Argentina	Novartis Pharmaceutical Manufacturing GmbH	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Argentina	Corden Pharma SpA	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Australia	Novartis Pharmaceuticals Canada, Inc.	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Canada	Corden Pharma SpA	03 Oct 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05192941 (VICTORION-Difference \| V-DIFFERENCE, NEWS) Manual	Phase 4	Hypercholesterolemia	1,770	Inclisiran sodium 300 mg	bkcxzaurdt(gagghzquom) = sajqgxuvfz yljvwsijdu (ilkyafdeer ) Met View more	Positive	30 Aug 2025
				Placebo	bkcxzaurdt(gagghzquom) = arrrprivkw yljvwsijdu (ilkyafdeer ) Met View more
NCT05763875 (V-MONO \| VICTORION-Mono, CTgov)	Phase 3	Primary hypercholesterolemia	350	Matching Placebo for Ezetimibe+Inclisiran (Inclisiran)	iqykmktxam(vnfaxxplhu) = hkdsqeskii jryrnbctov (iqacytyvzc, bcxyagrpzm - nrwuzhyjml) View more	-	13 Aug 2025
				Matching Placebo for Inclisiran+Ezetimibe (Ezetimibe)	iqykmktxam(vnfaxxplhu) = fixiqvyihk jryrnbctov (iqacytyvzc, lqalvzlurb - drizhossao) View more
NCT05763875 (VICTORION-Mono, Pubmed) Manual	Phase 3	Hypercholesterolemia	350	Inclisiran	lzxfpkukch(xlcjkshlqk) = ikdhflgnxw ypnauhgetg (dtlcdfyeyo )	Positive	01 Jul 2025
				Ezetimibe	lzxfpkukch(xlcjkshlqk) = ywldghzght ypnauhgetg (dtlcdfyeyo )
NCT04652726 (ORION-16, CTgov)	Phase 3	Heterozygous familial hypercholesterolemia	141	Inclisiran sodium (Part 1- Inclisiran)	gmminvpuuk(gcrzbzvbze) = xmgnfjqyfz eedseweewi (xyzsjzhkmb, lyebdmhpsz - grorrwoayd) View more	-	10 Jun 2025
				Placebo (Part 1 - Placebo)	gmminvpuuk(gcrzbzvbze) = viyyddqmjy eedseweewi (xyzsjzhkmb, udwhphydhg - qmthgbfqxn) View more
NCT04659863 (ORION-13, CTgov)	Phase 3	Homozygous familial hypercholesterolemia	13	Placebo (Part 1 - Placebo)	uiwhcxrxln(xjrtcvnidw) = kibwdlickp mwrnlutuxq (zmcyglfsyv, 30.52) View more	-	31 May 2025
				Inclisiran (Part 2 - Inclisiran (Total))	auqrbsjtue(npuvfcvrqm) = cjeceyzrcv qaflbhtwbt (jzsjrlimkj, 25.28) View more
NCT05888103 (V-Mono China, CTgov)	Phase 3	Dyslipidemias \| Primary hypercholesterolemia	207	Matching Placebo for Inclisiran+Inclisiran (Inclisiran - Inclisiran)	uhqyxeatzc(oyflzdfgil) = hnqgqfqlgd ibwjszuhqz (hidwxpismc, skjsywmfqf - zujkhldycx) View more	-	20 Apr 2025
				Matching Placebo for Inclisiran+Inclisiran (Placebo- Inclisiran)	uhqyxeatzc(oyflzdfgil) = pbohnixdel ibwjszuhqz (hidwxpismc, wnwjovcduw - jhddyhvxdj) View more
ORION-18 (NEWS) Manual	Phase 3	Atherosclerosis	232	英克司兰钠 300 mg	jfnaeukqek(mbnconmhhq) = pxuhkyetbn hynejniqse (tkmvnxwhhi ) View more	Positive	06 Mar 2025
				安慰剂	jfnaeukqek(mbnconmhhq) = fqbgakxcit hynejniqse (tkmvnxwhhi )
NCT03814187 (ORION-8, Pubmed \| Cardiovasc Res)	Phase 2/3	Hyper LDL cholesterolaemia \| Homozygous familial hypercholesterolemia \| Heterozygous familial hypercholesterolemia	3,274	Inclisiran	qcnowquvtr(tmzctbwxmu) = 5.9% of inclisiran-treated patients dxeguygkdw (ovvphumcco )	Positive	14 Oct 2024
ESC2024	Not Applicable	-	-	Inclisiran	cdkvysfqhz(xpfcvesgcs) = zjpeafkbmk cvwmyrsjrb (xkflbsabjk ) View more	-	31 Aug 2024
ESC2024	Not Applicable	-	-	Inclisiran + Usual Care	hdgoqdzloc(aovmecjegv) = Incidence of treatment-emergent adverse events (TEAEs) and serious TEAEs compared similarly between IF and UC for each subgroup (IF: 35.5−69.2%, UC: 34.2−84.2%, and IF: 3.2−16.9%, UC: 0.0−36.8%, respectively) ccxefhoskb (pmnvjdvksj )	-	30 Aug 2024